AstraZeneca eyes $80 billion Total Revenue by 2030 and sustained growth post 2030

 

• Launch of 20 new medicines expected by 2030
• Significant growth from existing oncology, biopharmaceuticals and rare disease portfolios
• Investing in disruptive innovation that will shape the future of medicine and drive long-term growth
• Decoupling carbon emissions from revenue growth

https://www.biospace.com/article/releases/astrazeneca-sets-ambition-to-deliver-80-billion-total-revenue-by-2030-and-sustained-growth-post-2030/